Challenges and Opportunities for Collaboration Between Academic Biobanks and Industry: Results of an International Survey of Academic Biobanks.

When it comes to collaboration between academic biobanks and the pharmaceutical/biotechnology industry, the criteria for effective collaborations are still unclear. Researchers in industry and academic biobanks can have different incentives and requirements that the other party is often not familiar with. This survey was conducted in an attempt to increase understanding of these fundamental knowledge gaps that may be obstacles to optimal collaboration between academia and industry. There were 53 total respondents. Although this was a global survey, most respondents ( = 29) were from North America, likely reflecting overall investment in research in this region and possibly increased interactions between academia and industry as well. Most respondent academic biobanks collect multiple sample types with most (>90%) collecting both biofluids (including blood) and tissue. Most of the participating academic biobanks were aware that they were not (35%), or only partially (35%), using the full potential of their inventory. One option for increasing utilization rates is by collaborating with industry partners. The main issues when working with industry were perceived to be a combination of challenges including contractual (55%), consent restrictions (45%), timelines (41%), or time pressure (36%). Time taken to put agreements together was also a significant hurdle (54%), together with the industry's administrative requirements (36%). To take advantage of opportunities for joint collaboration, it is essential that the parties involved build trust. The first step is to understand the different requirements and needs of the other party and to establish efficient structures for joint cooperation. This survey has highlighted key areas to be addressed as the next steps for strengthening bonds between academic biobanks and industry partners.